BPC-157
# BPC-157: A Pentadecapeptide Studied in Tissue Repair and Cytoprotection
**Research summary.** BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a stable fragment of a larger protein originally isolated from human gastric juice. The Sikiric laboratory in Zagreb, Croatia, has produced the most extensive body of preclinical work on the molecule over the past three decades, characterising its activity across gastrointestinal, musculoskeletal, vascular, and central nervous system models.
## Molecular profile
– **Sequence:** Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
– **Molecular formula:** C₆₂H₉₈N₁₆O₂₂
– **Molecular weight:** ~1419.5 g/mol
– **PubChem CID:** 108101
– **Stability:** Notably stable in human gastric juice, which has supported its evaluation by oral and parenteral routes in animal studies
## Mechanism of action
BPC-157 does not appear to act through a single canonical receptor. The current mechanistic picture, assembled across many rodent studies, points to a multi-system cytoprotective profile:
– **Angiogenesis via the VEGFR2/eNOS axis.** Cell-culture and chick chorioallantoic membrane assays have linked BPC-157 to upregulation of VEGFR2 signalling and downstream nitric-oxide-mediated endothelial cell migration and tubulogenesis [1].
– **Modulation of growth-hormone receptor expression.** Tendon and ligament studies have shown increased GH receptor expression in tenocytes following BPC-157 exposure, which has been proposed as a contributor to its connective-tissue effects.
– **Effects on the nitric oxide system.** BPC-157 has been reported to counter both the hypotensive effects of L-NAME (a NOS inhibitor) and the hypertensive effects of L-arginine, suggesting a balancing rather than directly stimulatory role in NO signalling.
– **Recruitment of fibroblasts.** Dose-dependent stimulation of fibroblast proliferation, migration, and F-actin polymerisation has been shown in vitro and in vivo, with associated phosphorylation of paxillin and FAK along the cell-migration pathway.
## Preclinical research highlights
**Gastrointestinal protection.** The original line of investigation. BPC-157 has been shown in rodent models to accelerate healing of gastric and duodenal ulcers, attenuate damage from NSAIDs, alcohol, and cysteamine, and protect intestinal anastomoses. The molecule has also been examined in models of inflammatory bowel disease and short-bowel syndrome [1].
**Tendon, ligament, and muscle injury.** A widely cited body of rat work has reported accelerated healing of transected Achilles tendons, medial collateral ligaments, and quadriceps muscle following systemic or local BPC-157 administration, with associated increases in fibroblast density and neovascularisation. The Sikiric group has published comparison data suggesting effects exceeding those of bFGF, EGF, and VGF on selected histological endpoints in rat models [2].
**Vascular models.** Rat ischaemia models have demonstrated rapid recruitment of collateral circulation following BPC-157 administration, including in cases of hepatic vein occlusion (Pringle manoeuvre), abdominal aorta clamping, and middle cerebral artery occlusion. The molecule has been described as activating “alternative bypass loops” through pre-existing vascular connections.
**Drug-induced toxicity.** Rat studies have reported attenuation of QTc prolongation, catalepsy, and other adverse effects of antipsychotics, NSAIDs, and certain anaesthetic agents. Hepatoprotective effects against paracetamol overdose have also been documented in rodents.
**Central nervous system.** Preclinical work has examined BPC-157 in models of haloperidol-induced catalepsy, MPTP-induced parkinsonism, traumatic brain injury, and spinal cord injury, with reported attenuation of behavioural and histological markers.
**Antioxidant effects.** Rat studies have shown reduced malondialdehyde and reactive oxygen species in tissue exposed to oxidative stress in the presence of BPC-157.
## Limitations of the current evidence base
Despite the breadth of reported effects, several caveats warrant explicit mention:
– A large fraction of the published literature originates from a single research group, which raises questions about independent replication that have been noted in critical reviews.
– No completed human clinical trials of BPC-157 are listed in the major registries at the time of writing. Reports of human use circulating in non-academic literature are not equivalent to clinical evidence.
– The mechanism of action remains incompletely defined; the absence of an identified canonical receptor makes pharmacological characterisation unusually difficult.
– BPC-157 is on the WADA Prohibited List as of 2022, classified under S0 (non-approved substances).
## Current research status
BPC-157 remains an **investigational research peptide**. It is widely used as a tool compound in preclinical wound-healing, tendon-repair, and gastrointestinal injury research, and is the subject of ongoing academic mechanistic investigation, particularly with respect to its angiogenic and nitric-oxide-modulating activities. It has not been approved as a therapeutic by any major regulatory authority.
## Key takeaways for researchers
– BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protein fragment.
– It exhibits broad cytoprotective and pro-angiogenic activity across rodent models, with no identified canonical receptor target.
– The largest body of work comes from a single laboratory; independent replication of key findings is important to monitor.
– BPC-157 is on the WADA Prohibited List and is not an approved therapeutic.
## References
1. Sikiric P, Seiwerth S, Rucman R, et al. *Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.* Current Neuropharmacology. 2016;14(8):857–865.
2. Cerovecki T, Bojanic I, Brcic L, et al. *Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.* Journal of Orthopaedic Research. 2010;28(9):1155–1161.
—
*This article is provided for educational and research purposes only. BPC-157 is an investigational research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. BPC-157 is listed by the World Anti-Doping Agency as a prohibited substance. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.*